Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Century Therapeutics, Inc.
  6. News
  7. Summary
    IPSC   US15673T1007

CENTURY THERAPEUTICS, INC.

(IPSC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Century Therapeutics, Bristol Myers Squibb Sign Cancer Research Collaboration Agreement

01/10/2022 | 08:24am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 0.56% 77.13 Delayed Quote.23.02%
CENTURY THERAPEUTICS, INC. -5.53% 8.37 Delayed Quote.-44.14%
STEM, INC. -10.80% 6.94 Delayed Quote.-58.99%
All news about CENTURY THERAPEUTICS, INC.
05/23HC Wainwright Starts Century Therapeutics at Buy With $27 Price Target
MT
05/17Piper Sandler Adjusts Century Therapeutics' Price Target to $22 From $38, Reiterates Ov..
MT
05/16Century Therapeutics Q1 Net Loss Narrows; Posts Revenue of $1.1 Million
MT
05/16CENTURY THERAPEUTICS, INC. Management's discussion and analysis of financial condition..
AQ
05/16Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/16Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business..
GL
05/12William Blair Initiates Coverage on Century Therapeutics With Market Perform Rating
MT
05/10CENTURY THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/03Century Therapeutics to Present at Upcoming Investor Conferences
GL
05/03Century Therapeutics to Present at Upcoming Investor Conferences
GL
More news
Analyst Recommendations on CENTURY THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 218 M - -
Net income 2022 -133 M - -
Net cash 2022 127 M - -
P/E ratio 2022 -3,89x
Yield 2022 -
Capitalization 521 M 521 M -
EV / Sales 2022 1,81x
EV / Sales 2023 19,4x
Nbr of Employees 179
Free-Float 63,4%
Chart CENTURY THERAPEUTICS, INC.
Duration : Period :
Century Therapeutics, Inc. Technical Analysis Chart | IPSC | US15673T1007 | MarketScreener
Technical analysis trends CENTURY THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 8,86 $
Average target price 25,00 $
Spread / Average Target 182%
EPS Revisions
Managers and Directors
Osvaldo Flores Chief Executive Officer & Director
Douglas Carr Vice President-Finance & Operations
Joseph Jimenez Chairman
Hyam I. Levitsky President-Research & Development
Luis Borges Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CENTURY THERAPEUTICS, INC.-44.14%521
MODERNA, INC.-45.81%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-27.91%38 497
SEAGEN INC.-9.87%25 649
ICON PUBLIC LIMITED COMPANY-29.74%17 688